589
Views
18
CrossRef citations to date
0
Altmetric
Original Article

Histone deacetylase inhibitors restore IL-10 expression in lipopolysaccharide-induced cell inflammation and reduce IL-1β and IL-6 production in breast silicone implant in C57BL/6J wild-type murine model

, , , , , , , , , , & show all
Pages 155-165 | Received 13 Aug 2015, Accepted 16 Dec 2015, Published online: 20 Jan 2016

References

  • Kollar, J., and V. Frecer. 2015. Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer. Curr. Pharm. Des. 21: 1472–1502
  • Mai, A., S. Massa, D. Rotili, et al. 2005. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. 25: 261–309
  • Didonna, A., and P. Opal. 2015. The promise and perils of HDAC inhibitors in neurodegeneration. Ann. Clin. Transl. Neurol. 2: 79–101
  • Dietz, K. C., and P. Casaccia. 2010. HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol. Res. 62: 11–17
  • Mai, A., D. Rotili, S. Valente, and A. G. Kazantsev. 2009. Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr. Pharm. Des. 15: 3940–3957
  • Dinarello, C. A. 2010. Anti-inflammatory agents: present and future. Cell 140: 935–950
  • Licciardi, P. V., K. Ververis, M. L. Tang, et al. 2013. Immunomodulatory effects of histone deacetylase inhibitors. Curr. Mol. Med. 13: 640–647
  • Grabiec, A. M., S. Krausz, W. de Jager, et al. 2010. Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J. Immunol. 184: 2718–2728
  • Leoni, F., A. Zaliani, and G. Bertolini, et al. 2002. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. USA 99: 2995–3000
  • Chung, Y. L., M. Y. Lee, A. J. Wang, and L. F. Yao. 2003. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol. Ther. 8: 707–717
  • Cantley, M. D., and D. R. Haynes. 2013. Epigenetic regulation of inflammation: progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs. Inflammopharmacology 21: 301–307
  • Chen, X., I. Barozzi, A. Termanini, et al. 2012. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc. Natl. Acad. Sci. USA 109: E2865–E2874
  • de Zoeten, E. F., L. Wang, K. Butler, et al. 2011. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol. Cell. Biol. 31: 2066–2078
  • Jeong, Y., R. Du, X. Zhu, et al. 2014. Histone deacetylase isoforms regulate innate immune responses by deacetylating mitogen-activated protein kinase phosphatase-1. J. Leukoc. Biol. 95: 651–659
  • Meza Britez, M. E., C. Caballero Llano, and A. Chaux. 2012. Periprosthetic breast capsules and immunophenotypes of inflammatory cells. Eur J Plast Surg. 35: 647–651
  • Berry, M. G., V. Cucchiara, and D. M. Davies. 2010. Breast augmentation: part II – adverse capsular contracture. J. Plast. Reconstr. Aesthet. Surg. 63: 2098–2107
  • McLean, A. L., M. Talmor, A. Harper, et al. 2002. Expression of cyclooxygenase-2 in the periprosthetic capsule surrounding a silicone shell implant in the rat. Ann. Plast. Surg. 48: 292–297
  • Poeppl, N., S. Schreml, F. Lichtenegger, et al. 2007. Does the surface structure of implants have an impact on the formation of a capsular contracture? Aesthetic Plast. Surg. 31: 133–139
  • Brazin, J., S. Malliaris, B. Groh, et al. 2014. Mast cells in the periprosthetic breast capsule. Aesthetic Plast. Surg. 38: 592–601
  • Zimman, O. A., J. Tobli, L. Stella, et al. 2007. The effects of angiotensin-converting enzyme inhibitors on the fibrous envelope around mammary implants. Plast. Reconstr. Surg. 120: 2025–2033
  • Huang, C. K., and N. Handel. 2010. Effects of Singulair (montelukast) treatment for capsular contracture. Aesthet. Surg. J. 30: 404–408
  • Scuderi, N., M. Mazzocchi, and C. Rubino. 2007. Effects of zafirlukast on capsular contracture: controlled study measuring the mammary compliance. Int. J. Immunopathol. Pharmacol. 20: 577–584
  • Lina, C., W. Conghua, L. Nan, and Z. Ping. 2011. Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis. J. Clin. Immunol. 31: 596–605
  • Leoni, F., G. Fossati, and E. C. Lewis, et al. 2005. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 11: 1–15
  • Grabiec, A. M., O. Korchynskyi, P. P. Tak, and K. A. Reedquist. 2012. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann. Rheum. Dis. 71: 424–431
  • Han, S. B., and J. K. Lee. 2009. Anti-inflammatory effect of Trichostatin-A on murine bone marrow-derived macrophages. Arch. Pharm. Res. 32: 613–624
  • Glauben, R., A. Batra, I. Fedke, et al. 2006. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176: 5015–5022
  • Li, Y., B. Liu, and H. Zhao, et al. 2009. Protective effect of suberoylanilide hydroxamic acid against LPS-induced septic shock in rodents. Shock 32: 517–523
  • Nasu, Y., K. Nishida, S. Miyazawa, et al. 2008. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartil. 16: 723–732
  • Joosten, L. A., F. Leoni, S. Meghji, and P. Mascagni. 2011. Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis. Mol. Med. 17: 391–396
  • Gillespie, J., S. Savic, C. Wong, et al. 2012. Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Rheum. 64: 418–422
  • Butler, K. V., J. Kalin, C. Brochier, et al. 2010. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc. 132: 10842–10846
  • Akimova, T., G. Ge, T. Golovina, et al. 2010. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin. Immunol. 136: 348–363
  • Saouaf, S. J., B. Li, G. Zhang, et al. 2009. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp. Mol. Pathol. 87: 99–104
  • Tao, R., E. F. de Zoeten, E. Ozkaynak, et al. 2007. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13: 1299–1307
  • Li, S., G. Fossati, and C. Marchetti, et al. 2015. Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo. J. Biol. Chem. 290: 2368–2378
  • Mai, A., S. Massa, R. Pezzi, et al. 2005a. Synthesis and biological evaluation of 2-, 3-, and 4-acylaminocinnamyl-N-hydroxyamides as novel synthetic HDAC inhibitors. Med. Chem. 1: 245–254
  • Thaler, F., M. Varasi, A. Colombo, et al. 2010. Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors. ChemMedChem 5: 1359–1372
  • Thaler, F., A. Colombo, A. Mai, et al. 2010a. Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors. J. Med. Chem. 53: 822–839
  • Valente, S., M. Tardugno, M. Conte, et al. 2011. Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity. ChemMedChem 6: 698–712
  • Yang, F., T. Zhang, H. Wu, et al. 2014. Design and optimization of novel hydroxamate-based histone deacetylase inhibitors of Bis-substituted aromatic amides bearing potent activities against tumor growth and metastasis. J. Med. Chem. 57: 9357–9369
  • Valente, S., D. Trisciuoglio, M. Tardugno, et al. 2013. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells. ChemMedChem 8: 800–811
  • Di Pompo, G., M. Salerno, D. Rotili, et al. 2015. Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells. J. Med. Chem. 58: 4073–4079
  • Bancroft, J. D., and M. Gamble. 2008. Theory and Practice of Histological Techniques, 6th edn. Philadelphia (PA), USA: Elsevier Health Sciences
  • Lee, J. H., M. L. Choy, and P. A. Marks. 2012. Mechanisms of resistance to histone deacetylase inhibitors. Adv. Cancer Res. 116: 39–86
  • Spits, H., and R. de Waal Malefyt. 1992. Functional characterization of human IL-10. Int. Arch. Allergy Immunol. 99: 8–15
  • Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19: 683–765
  • Grewe, M., K. Gyufko, and J. Krutmann. 1995. Interleukin-10 production by cultured human keratinocytes: regulation by ultraviolet B and ultraviolet A1 radiation. J. Invest. Dermatol. 104: 3–6
  • Hacham, M., R. M. White, S. Argov, et al. 2004. Interleukin-6 and interleukin-10 are expressed in organs of normal young and old mice. Eur. Cytokine Netw. 15: 37–46
  • Ingerslev, H. C., C. G. Ossum, T. Lindenstrom, and M. E. Nielsen. 2010. Fibroblasts express immune relevant genes and are important sentinel cells during tissue damage in rainbow trout (Oncorhynchus mykiss). PLoS One 5: e9304
  • Licciardi, P. V., and T. C. Karagiannis. 2012. Regulation of immune responses by histone deacetylase inhibitors. ISRN Hematol. 2012: 690901
  • Cao, W., C. Bao, E. Padalko, and C. J. Lowenstein. 2008. Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. J. Exp. Med. 205: 1491–1503
  • Daan de Boer, J., J. J. Roelofs, A. F. de Vos, et al. 2013. Lipopolysaccharide inhibits Th2 lung inflammation induced by house dust mite allergens in mice. Am. J. Respir. Cell. Mol. Biol. 48: 382–389
  • Laitung, J. K., J. McClure, and C. A. Shuttleworth. 1987. The fibrous capsules around static and dynamic implants: their biochemical, histological, and ultrastructural characteristics. Ann. Plast. Surg. 19: 208–216
  • Wolfram, D., C. Rainer, H. Niederegger, et al. 2004. Cellular and molecular composition of fibrous capsules formed around silicone breast implants with special focus on local immune reactions. J Autoimmunity 23: 81–91
  • Minami, E., I. H. Koh, J. C. Ferreira, et al. 2006. The composition and behavior of capsules around smooth and textured breast implants in pigs. Plast. Reconstr. Surg. 118: 874–884
  • Deknuydt, F., G. Bioley, D. Valmori, and M. Ayyoub. 2009. IL-1β and IL-2 convert human Treg into T H 17 cells. Clin. Immunol. 131: 298–307
  • Joseph, J., K. T. Variathu, and M. Mohanty. 2013. Mediatory role of interleukin-6 in α-smooth muscle actin induction and myofibroblast formation around silicone tissue expander. J. Biomed. Mater. Res. A. 101: 2967–2973
  • Levings, M. K., R. Bacchetta, U. Schulz, and M. G. Roncarolo. 2002. The role of IL-10 and TGF-β in the differentiation and effector function of T regulatory cells. Int. Arch. Allergy Immunol. 129: 263–276
  • Reitamo, S., A. Remitz, K. Tamai, and J. Uitto. 1994. Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J. Clin. Invest. 94: 2489–2492
  • Schmidt, S. C., S. E. Logan, J. M. Hayden, et al. 1991. Continuous versus conventional tissue expansion: experimental verification of a new technique. Plast Reconstr Surg. 87: 10–15
  • Pang, M., and S. Zhuang. 2010. Histone deacetylase: a potential therapeutic target for fibrotic disorders. J. Pharmacol. Exp. Ther. 335: 266–272
  • Choudhary, C., C. Kumar, F. Gnad, et al. 2009. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834–840
  • Akimova, T., U. H. Beier, Y. Liu, et al. 2012. Histone/protein deacetylases and T-cell immune responses. Blood 119: 2443–2451
  • Maynard, C. L., and C. T. Weaver. 2008. Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol. Rev. 226: 219–233
  • Gaston, J. S. 1989. Lymphokines in inflammation. Autoimmunity 4: 143–147
  • Hinz, B. 2007. Formation and function of the myofibroblast during tissue repair. J. Invest. Dermatol. 127: 526–537
  • Glenisson, W., V. Castronovo, D. Waltregny. 2007. Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim. Biophys. Acta 1773: 1572–1582
  • Rombouts, K., T. Niki, P. Greenwel, et al. 2002. Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts. Exp. Cell Res. 278: 184–197
  • Barter, M. J., L. Pybus, G. J. Litherland, et al. 2010. HDAC-mediated control of ERK- and PI3K-dependent TGF-β-induced extracellular matrix-regulating genes. Matrix Biol. 29: 602–612
  • Chen, C. Z., and M. Raghunath. 2009. Focus on collagen: in vitro systems to study fibrogenesis and antifibrosis state of the art. Fibrogenesis Tissue Repair. 2: 7
  • Asadullah, K., W. Sterry, and H. D. Volk. 2003. Interleukin-10 therapy – review of a new approach. Pharmacol. Rev. 55: 241–269
  • Villagra, A., F. Cheng, H. W. Wang, et al. 2009. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat. Immunol. 10: 92–100

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.